RT - Journal Article T1 - B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease JF - gums-cjns YR - 2017 JO - gums-cjns VO - 3 IS - 1 UR - http://cjns.gums.ac.ir/article-1-154-en.html SP - 46 EP - 53 K1 - B cell K1 - Therapy K1 - Giant Axonal Neuropathy K1 - Mixed Connective Tissue Disease AB - The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells. Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells. The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies. LA eng UL http://cjns.gums.ac.ir/article-1-154-en.html M3 10.18869/acadpub.cjns.3.8.46 ER -